Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan

Tetsuhide Ito, Susumu Hijioka, Toshihiko Masui, Atsuko Kasajima, Yuji Nakamoto, Noritoshi Kobayashi, Izumi Komoto, Masayuki Hijioka, Lingaku Lee, Hisato Igarashi, Robert Thomas Jensen, Masayuki Imamura

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the treatment response of neuroendocrine neoplasm (NEN), has been demonstrated in Japan. For PNEN diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20 % according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorly differentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed. Additionally, somatostatin receptor type 2 is expressed in several cases of NET, and somatostatin receptor scintigraphy (111In-octreoscan) has also been approved in Japan. This advancement will undoubtedly contribute to the localization diagnosis, the identification of remote metastasis, and assessments of the treatment responses of PNEN. Finally, regarding the treatment strategy for PNEN, the management of liver metastasis is important. The advent of novel molecular-targeted agents has dramatically improved the prognosis of advanced PNEN. Multimodality therapy that accounts for the tumor stage, degree of tumor differentiation, tumor volume, and speed of tumor growth is required.

Original languageEnglish
Pages (from-to)9-18
Number of pages10
JournalJournal of gastroenterology
Volume52
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Pancreatic Neoplasms
Japan
Neuroendocrine Tumors
Endosonography
Fine Needle Biopsy
Therapeutics
Neoplasms
Neoplasm Metastasis
Neuroendocrine Carcinoma
Chromogranin A
Somatostatin Receptors
Tumor Burden
Radionuclide Imaging
Mutation
Liver
Growth
Genes

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Ito, T., Hijioka, S., Masui, T., Kasajima, A., Nakamoto, Y., Kobayashi, N., ... Imamura, M. (2017). Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. Journal of gastroenterology, 52(1), 9-18. https://doi.org/10.1007/s00535-016-1250-9

Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. / Ito, Tetsuhide; Hijioka, Susumu; Masui, Toshihiko; Kasajima, Atsuko; Nakamoto, Yuji; Kobayashi, Noritoshi; Komoto, Izumi; Hijioka, Masayuki; Lee, Lingaku; Igarashi, Hisato; Jensen, Robert Thomas; Imamura, Masayuki.

In: Journal of gastroenterology, Vol. 52, No. 1, 01.01.2017, p. 9-18.

Research output: Contribution to journalReview article

Ito, T, Hijioka, S, Masui, T, Kasajima, A, Nakamoto, Y, Kobayashi, N, Komoto, I, Hijioka, M, Lee, L, Igarashi, H, Jensen, RT & Imamura, M 2017, 'Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan', Journal of gastroenterology, vol. 52, no. 1, pp. 9-18. https://doi.org/10.1007/s00535-016-1250-9
Ito, Tetsuhide ; Hijioka, Susumu ; Masui, Toshihiko ; Kasajima, Atsuko ; Nakamoto, Yuji ; Kobayashi, Noritoshi ; Komoto, Izumi ; Hijioka, Masayuki ; Lee, Lingaku ; Igarashi, Hisato ; Jensen, Robert Thomas ; Imamura, Masayuki. / Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. In: Journal of gastroenterology. 2017 ; Vol. 52, No. 1. pp. 9-18.
@article{14ac98569fbd4005bcda5f5f849dcd95,
title = "Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan",
abstract = "Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the treatment response of neuroendocrine neoplasm (NEN), has been demonstrated in Japan. For PNEN diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20 {\%} according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorly differentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed. Additionally, somatostatin receptor type 2 is expressed in several cases of NET, and somatostatin receptor scintigraphy (111In-octreoscan) has also been approved in Japan. This advancement will undoubtedly contribute to the localization diagnosis, the identification of remote metastasis, and assessments of the treatment responses of PNEN. Finally, regarding the treatment strategy for PNEN, the management of liver metastasis is important. The advent of novel molecular-targeted agents has dramatically improved the prognosis of advanced PNEN. Multimodality therapy that accounts for the tumor stage, degree of tumor differentiation, tumor volume, and speed of tumor growth is required.",
author = "Tetsuhide Ito and Susumu Hijioka and Toshihiko Masui and Atsuko Kasajima and Yuji Nakamoto and Noritoshi Kobayashi and Izumi Komoto and Masayuki Hijioka and Lingaku Lee and Hisato Igarashi and Jensen, {Robert Thomas} and Masayuki Imamura",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00535-016-1250-9",
language = "English",
volume = "52",
pages = "9--18",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan

AU - Ito, Tetsuhide

AU - Hijioka, Susumu

AU - Masui, Toshihiko

AU - Kasajima, Atsuko

AU - Nakamoto, Yuji

AU - Kobayashi, Noritoshi

AU - Komoto, Izumi

AU - Hijioka, Masayuki

AU - Lee, Lingaku

AU - Igarashi, Hisato

AU - Jensen, Robert Thomas

AU - Imamura, Masayuki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the treatment response of neuroendocrine neoplasm (NEN), has been demonstrated in Japan. For PNEN diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20 % according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorly differentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed. Additionally, somatostatin receptor type 2 is expressed in several cases of NET, and somatostatin receptor scintigraphy (111In-octreoscan) has also been approved in Japan. This advancement will undoubtedly contribute to the localization diagnosis, the identification of remote metastasis, and assessments of the treatment responses of PNEN. Finally, regarding the treatment strategy for PNEN, the management of liver metastasis is important. The advent of novel molecular-targeted agents has dramatically improved the prognosis of advanced PNEN. Multimodality therapy that accounts for the tumor stage, degree of tumor differentiation, tumor volume, and speed of tumor growth is required.

AB - Several new developments have occurred in the field of pancreatic neuroendocrine neoplasm (PNEN) recently in Japan. First, the utility of chromogranin A (CgA), useful for the diagnosis and monitoring of the treatment response of neuroendocrine neoplasm (NEN), has been demonstrated in Japan. For PNEN diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20 % according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorly differentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed. Additionally, somatostatin receptor type 2 is expressed in several cases of NET, and somatostatin receptor scintigraphy (111In-octreoscan) has also been approved in Japan. This advancement will undoubtedly contribute to the localization diagnosis, the identification of remote metastasis, and assessments of the treatment responses of PNEN. Finally, regarding the treatment strategy for PNEN, the management of liver metastasis is important. The advent of novel molecular-targeted agents has dramatically improved the prognosis of advanced PNEN. Multimodality therapy that accounts for the tumor stage, degree of tumor differentiation, tumor volume, and speed of tumor growth is required.

UR - http://www.scopus.com/inward/record.url?scp=84982256015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982256015&partnerID=8YFLogxK

U2 - 10.1007/s00535-016-1250-9

DO - 10.1007/s00535-016-1250-9

M3 - Review article

AN - SCOPUS:84982256015

VL - 52

SP - 9

EP - 18

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 1

ER -